Innovent Buys Into Ascentage, Opening New China Biopharma Chapter
Combining Small, Large Molecule Expertise
The unprecedented deal between two public Chinese biotechs, Innovent Biologics and Ascentage Pharma, potentially provides an opening for more such mega-million dollar deals to come.
You may also be interested in...
Volume gains from the entry into China’s national reimbursement program offset deep price cut for AstraZeneca’s major selling Tagrisso in the second quarter of 2021.
Sales of the Swiss drug maker's major plaque psoriasis treatment Cosentyx in China quadrupled in the second quarter, despite its price being slashed by more than 60%.
China's top regulator grants approvals to a record number of novel drugs, including multiple oncology products from domestic companies, which are increasingly shifting to innovation, supported by positive regulatory changes over the past few years.